Описание
Both empagliflozin and furosemide promote natriuresis and diuresis; concurrent use can produce additive volume depletion, hypotension, and electrolyte disturbances.
Механизм
Empagliflozin inhibits SGLT2 in the proximal tubule, causing glucosuria, natriuresis, and osmotic diuresis; furosemide blocks the Na-K-2Cl transporter in the loop of Henle. Combined diuretic effects can cause dehydration and orthostatic hypotension.
Клиническое значение
Clinical trials and post-marketing data show increased rates of volume depletion-related adverse events (hypotension, dizziness, acute kidney injury) with SGLT2 inhibitor and loop diuretic combinations, especially in elderly patients.
Тактика ведения
Assess volume status before and after initiating empagliflozin in patients on loop diuretics; consider dose reduction of furosemide; monitor blood pressure, renal function, and electrolytes closely.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.